Sökning: "Thrombin inhibitor"

Visar resultat 11 - 15 av 47 avhandlingar innehållade orden Thrombin inhibitor.

1. 11. Venous thromboembolism. Aspects on risk factors, diagnostic tools and treatment with thrombin inhibition

   Författare :Karin Wåhlander; Göteborgs universitet; []
   Nyckelord :deep vein thrombosis; pulmonary embolism; venous thromboembolism; Factor V Leiden; prothrombin gene G20210A; thrombin inhibition; ximelagatran; melagatran; PT; APTT; D-dimer.;

   Sammanfattning : Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a multifactorial disease. The aims of the present thesis were to investigate Factor V Leiden and prothrombin G20210A mutations as potential risk factors for VTE during and after major surgery, to compare different D-dimer assays and evaluate their usefulness in the diagnosis of DVT, to investigate clinical effects, safety and pharmacokinetic properties of an oral thrombin inhibitor (ximelagatran) when treating VTE and finally to investigate the usefulness of coagulation assays (APTT and PT) during treatment with thrombin inhibition. LÄS MER

3. 12. Experimental studies on thrombin inhibition in acute- and chronic models of vessel wall injury

   Författare :Fredrik Scherstén; Göteborgs universitet; []
   Nyckelord :animal model; antithrombin; fibrinogen; histomorphology; melagatran; percutaneous coronary intervention; platelets; restenosis; stent; thrombin inhibition; thrombosis;

   Sammanfattning : Background: The number of percutaneous coronary interventions (PCI) performed worldwide has increased dramatically during the last decade. Complication rates have decreased over time, however the restenosis phenomenon remains an unsolved issue. Thrombin is the key regulator in the pro-coagulant state following PCI. LÄS MER

4. 13. Inflammation and Coagulation Activity in Unstable Coronary Artery Disease and the Influences of Thrombin Inhibition

   Författare :Jonas Oldgren; Steen Husted; Uppsala universitet; []
   Nyckelord :Medical sciences; Unstable coronary artery disease; inflammation; coagulation; thrombin inhibition; MEDICIN OCH VÅRD; MEDICINE; MEDICIN; kardiologi; Cardiology;

   Sammanfattning : In patients with unstable coronary artery disease, this study evaluated the degree of inflammation and coagulation activity, relations to myocardial cell damage, prognosis, and influences of randomisation to 72 h infusion with three different doses of inogatran, a direct thrombin inhibitor (n=904), or unfractionated heparin (n=305). Anticoagulant treatment effects were evaluated with aPT time. LÄS MER

5. 14. Experimental studies on thrombosis and thrombolysis : With special reference to importance of lys-plasminogen, active site thrombin inhibitors and stable fish oil

   Författare :Liying Chen; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Surgery; Thrombolysis; thrombosis; recombinant tissue-type plasminogen activator; lys- and glu-plasminogen; aspirin; thrombin inhibitors; platelets; superoxide dismutase; stable fish oil; Kirurgi; Surgery; Kirurgi; rättsmedicin; Forensic Medicine;

   Sammanfattning : Dissolution and prevention of thrombus in the atherosclerotic coronary artery have become an important part of treatment therapy of acute myocardial infarction. However, the currently most effective thrombolytic agent, recombinant tissue-type plasminogen activator (rt-PA), only elicits 80% recanalization of thrombotically occluded coronary arteries and early occlusion occurs in about 40% of successfullyrecanalized vessels. LÄS MER

7. 15. Regulation of Tissue Factor and Coagulation Activity : Translation Studies with Focus on Platelet-Monocyte Aggregates and Patients with Acute Coronary Syndrome

   Författare :Christina Christersson; Agneta Siegbahn; Lars Wallentin; Jonas Oldgren; Ingebjorg Seljeflot; Uppsala universitet; []
   Nyckelord :Internal medicine; Myocardial infarction; Coagulation; Platelet-monocyte aggregates; Tissue factor; Thrombin inhibition; Invärtesmedicin;

   Sammanfattning : Myocardial infarction (MI) is often caused by a disruption of an atherosclerotic plaque with activation of coagulation, platelets and inflammation. The aims were; to investigate whether the oral direct thrombin inhibitor, ximelagatran affected markers for coagulation, platelet and inflammation in a patient cohort with recent MI and if the coagulation markers could identify patients with increased risk of new ischemic events; to evaluate some of the mechanisms involved in formation of platelet-monocyte aggregates (PMAs). LÄS MER